Posted by Michael Wonder on 13 Nov 2020
Highlights from 9-12 November CHMP meeting
13 November 2020 - The EMA’s CHMP recommended five medicines for approval at its November 2020 meeting.
The Committee recommended granting a marketing authorisation for Phesgo (pertuzumab/trastuzumab) for the treatment of early and metastatic breast cancer.
